Novel Nano-Platform for Targeted Liver Fibrosis Treatment

Researchers have introduced a promising approach for liver fibrosis treatment using a novel nanotechnology platform. However, liver fibrosis acts as a dangerous precursor to cirrhosis in patients with chronic liver diseases. Consequently, current clinical options often fail due to systemic side effects or low tissue specificity. Therefore, to overcome these barriers, scientists developed the Lac-AGly nanoparticle system. This platform utilizes natural glycogen as a biodegradable backbone. Notably, researchers modified the glycogen with lactobionic acid to target asialoglycoprotein receptors (ASGPR) on hepatocytes. For instance, this modification ensures that the therapeutic payload reaches the intended site with high precision.

Advancing Liver Fibrosis Treatment with siRNA

This system delivers small interfering RNA (siRNA) specifically designed to silence connective tissue growth factor (CTGF). Furthermore, the researchers achieved a 51.2% degree of amination on the glycogen backbone. This modification conferred efficient siRNA binding capacity. Specifically, the resulting nanocomplexes maintained a uniform spherical shape and an average particle size of 247.2 nm. Moreover, in vivo testing revealed remarkable results in animal models. In addition, the treatment reduced the collagen-positive area in the liver from 14.3% to just 3.1%. Consequently, this platform demonstrates significant potential for clinical translation. Overall, it offers a safe and effective way to achieve gene-silencing without harming healthy tissues.

Frequently Asked Questions

How does this nanoparticle system target the liver specifically?

The system uses lactobionic acid to recognize asialoglycoprotein receptors (ASGPR). These receptors are primarily expressed on the surface of hepatocytes. Therefore, the siRNA is delivered directly to the liver cells.

What is the role of CTGF in liver disease?

Connective tissue growth factor (CTGF) is a key protein that promotes the accumulation of collagen and scar tissue. Specifically, silencing this gene helps halt and reverse the fibrotic process.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

1. Gao M et al. A Hepatic-Targeted Glycogen-Based Nano-Platform Enables Efficient CTGF Silencing and Attenuates Liver Fibrosis. Nanotechnology. 2026 Feb 09. doi: 10.1088/1361-6528/ae435b. PMID: 41662774.


2. Kumar A et al. Nanotechnology in Drug Delivery for Liver Fibrosis. PMC. 2021.


3. Liu X et al. Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis. PMC. 2025.